share_log

Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Harrington Investments INC

Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Harrington Investments INC

哈靈頓投資公司出售的霍洛奇公司(納斯達克代碼:HOLX)股票
Financial News Live ·  2022/10/03 10:32

Harrington Investments INC reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,704 shares of the medical equipment provider's stock after selling 400 shares during the period. Harrington Investments INC's holdings in Hologic were worth $603,000 at the end of the most recent reporting period.

據哈靈頓投資公司在提交給美國證券交易委員會的最新文件中稱,該公司在第二季度將其在納斯達克公司(Sequoia Capital,Inc.)的股票持倉削減了4.4%。在此期間出售了400股後,該機構投資者持有這家醫療設備提供商的股票8,704股。在最近一個報告期結束時,哈靈頓投資公司在霍洛奇公司持有的股份價值603,000美元。

Several other institutional investors and hedge funds have also made changes to their positions in the company. Integrated Advisors Network LLC increased its position in Hologic by 17.1% in the first quarter. Integrated Advisors Network LLC now owns 3,800 shares of the medical equipment provider's stock worth $292,000 after buying an additional 555 shares during the period. Advisor Group Holdings Inc. increased its position in Hologic by 32.4% in the first quarter. Advisor Group Holdings Inc. now owns 38,475 shares of the medical equipment provider's stock worth $2,721,000 after buying an additional 9,410 shares during the period. McGuire Investment Group LLC increased its position in Hologic by 1.2% in the first quarter. McGuire Investment Group LLC now owns 147,777 shares of the medical equipment provider's stock worth $11,352,000 after buying an additional 1,818 shares during the period. Crossmark Global Holdings Inc. increased its position in Hologic by 56.5% in the first quarter. Crossmark Global Holdings Inc. now owns 43,727 shares of the medical equipment provider's stock worth $3,359,000 after buying an additional 15,780 shares during the period. Finally, CIBC Asset Management Inc increased its position in Hologic by 196.3% in the first quarter. CIBC Asset Management Inc now owns 71,148 shares of the medical equipment provider's stock worth $5,466,000 after buying an additional 47,134 shares during the period. 85.70% of the stock is owned by institutional investors and hedge funds.

其他幾家機構投資者和對衝基金也對他們在該公司的頭寸進行了調整。第一季度,集成顧問網絡有限責任公司將其在霍洛奇的頭寸增加了17.1%。集成顧問網絡有限責任公司現在擁有這家醫療設備提供商的3800股票,價值29.2萬美元,在此期間又購買了555股。Advisor Group Holdings Inc.在第一季度將其在霍洛奇的頭寸增加了32.4%。Advisor Group Holdings Inc.現在持有這家醫療設備提供商38,475股股票,價值2,721,000美元,在此期間又購買了9,410股。McGuire Investment Group LLC在第一季度將其在霍洛奇的頭寸增加了1.2%。麥奎爾投資集團現在擁有147,777股這家醫療設備提供商的股票,價值11,352,000美元,在此期間又購買了1,818股。今年第一季度,Crossmark Global Holdings Inc.將其在霍洛奇的持倉增加了56.5%。Crossmark Global Holdings Inc.現在持有這家醫療設備提供商43,727股股票,價值3,359,000美元,在此期間又購買了15,780股。最後,加拿大帝國商業銀行資產管理公司在第一季度將其在霍洛奇的頭寸增加了196.3%。加拿大帝國商業銀行資產管理公司(CIBC Asset Management Inc.)目前持有這家醫療設備提供商71,148股票,價值5,466,000美元,在此期間又購買了47,134股票。85.70%的股票由機構投資者和對衝基金持有。

Get
到達
Hologic
荷蘭學
alerts:
警報:

Wall Street Analyst Weigh In

華爾街分析師也加入進來

Several research analysts have recently issued reports on HOLX shares. BTIG Research cut Hologic from a "buy" rating to a "neutral" rating in a research note on Monday, July 18th. Bank of America cut Hologic from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $81.00 to $75.00 in a research note on Wednesday, July 20th. Morgan Stanley decreased their price target on Hologic from $72.00 to $70.00 and set an "equal weight" rating for the company in a research note on Thursday, July 28th. Finally, UBS Group started coverage on Hologic in a research note on Wednesday, July 20th. They issued a "neutral" rating and a $73.00 price target for the company. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Hologic has a consensus rating of "Hold" and an average target price of $76.71.

幾位研究分析師最近發佈了關於HOLX股票的報告。BTIG Research在7月18日星期一的一份研究報告中將霍洛奇的評級從“買入”下調至“中性”。美國銀行在7月20日星期三的一份研究報告中,將霍洛奇的評級從買入下調至中性,並將該股的目標價從81.00美元下調至75.00美元。摩根士丹利在7月28日週四的一份研究報告中將他們對霍洛奇的目標價從72.00美元下調至70.00美元,併為該公司設定了“同等權重”的評級。最後,瑞銀集團在7月20日星期三的一份研究報告中開始對霍洛奇進行報道。他們對該公司的評級為中性,目標價為73.00美元。七位分析師對該股的評級為持有,四位分析師對該公司股票的評級為買入。根據MarketBeat.com的數據,霍洛奇的普遍評級為持有,平均目標價為76.71美元。

Hologic Price Performance

高性價比

HOLX stock traded up $1.40 during trading hours on Monday, hitting $65.92. 2,996 shares of the stock traded hands, compared to its average volume of 1,760,696. The stock has a 50-day simple moving average of $68.85 and a 200 day simple moving average of $72.05. Hologic, Inc. has a one year low of $61.57 and a one year high of $80.49. The company has a market cap of $16.46 billion, a P/E ratio of 10.88, a P/E/G ratio of 0.73 and a beta of 1.02. The company has a current ratio of 3.91, a quick ratio of 3.32 and a debt-to-equity ratio of 0.57.
週一交易時段,HOLX股價上漲1.40美元,觸及65.92美元。該股有2,996股易手,而平均成交量為1,760,696股。該股的50日簡單移動均線切入位為68.85美元,200日簡單移動均線切入位為72.05美元。霍洛奇公司的一年低點為61.57美元,一年高位為80.49美元。該公司市值164.6億美元,市盈率10.88倍,市盈率0.73倍,貝塔係數1.02。該公司的流動比率為3.91,速動比率為3.32,債務權益比率為0.57。

Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $896.71 million. During the same quarter last year, the business posted $1.33 earnings per share. The company's quarterly revenue was down 14.2% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post 5.82 earnings per share for the current year.

霍洛奇公司(納斯達克代碼:HOLX-GET Rating)上一次公佈財報是在7月27日星期三。這家醫療設備提供商公佈本季度每股收益為0.95美元,比普遍預期的0.69美元高出0.26美元。霍洛奇的股本回報率為37.48%,淨利潤率為28.93%。該業務當季營收為10億美元,高於分析師預期的8.9671億美元。去年同一季度,該公司公佈的每股收益為1.33美元。該公司季度營收同比下降14.2%。股票分析師預測,霍洛奇公司本年度每股收益將達到5.82美元。

Hologic Profile

霍洛奇剖面

(Get Rating)

(獲取評級)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

霍洛奇公司在美國、歐洲、亞太地區和國際上開發、製造和供應診斷產品、醫學成像系統和外科產品,通過早期發現和治療來保護婦女的健康。它通過四個部分運作:診斷、乳房健康、婦科外科和骨骼健康。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Hologic (HOLX)
  • Near-Term Headwinds Send Nike To The Bargain Basement
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • Is the Bond Market Signaling a Market Bottom?
  • 免費獲取StockNews.com關於霍洛奇的研究報告(HOLX)
  • 近期的逆風將耐克送到了廉價地下室
  • 阿徹·丹尼爾斯·米德蘭:49年增長的紅利英雄
  • 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎?
  • 麥格納國際是您的汽車和電動汽車一站式庫存
  • 債券市場是否發出了市場觸底的信號?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Get Rating).

想看看其他對衝基金持有HOLX嗎?訪問HoldingsChannel.com獲取霍洛奇公司(納斯達克代碼:HOLX-GET Rating)的最新13F備案文件和內幕交易信息。

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

接受《荷蘭語日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對霍洛奇及相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論